Prev Close | 268.35 |
Open | 265.51 |
Day Low/High | 263.78 / 268.00 |
52 Wk Low/High | 176.36 / 292.75 |
Volume | 323.61K |
Prev Close | 268.35 |
Open | 265.51 |
Day Low/High | 263.78 / 268.00 |
52 Wk Low/High | 176.36 / 292.75 |
Volume | 323.61K |
Exchange | NASDAQ |
Shares Outstanding | 255.76B |
Market Cap | 66.14B |
P/E Ratio | 23.27 |
Div & Yield | N.A. (N.A) |
Let's start by taking a peek at the overnight and early-morning price action of the major asset classes. The rundown: S&P futures -4; Nasdaq futures -; Nikkei schmeissed for second day in a row, -3% and at the lowest level in three weeks (is Abe ret...
Stick with solid investing precepts.
We are seeing some hot pockets of momentum.
No setup for a bullish reaction to bullish news today.
It can turn so quickly and totally forget poor action.
The best thing to do is get out of the way and let it play out.
And the close put an exclamation point on it.
TheStreet senior columnist Adam Feuerstein explains why Vertex Pharmaceuticals is the next big thing in biotech.
Action in individual stocks was impressive despite the struggling indices.
The action just keeps chugging higher.
I'm going to spend some time developing my watch list for next week.
US stock futures are up amid earnings from GE and IBM. TheStreet's Debra Borchardt details.
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.
Traders are jockeying for position as we await the Fed, economic data and key earnings.
Senior columnist Adam Feuerstein says earnings from Dendreon and Vertex are the next big things in biotech.
Adam Feuerstein, Sr. Columnist for TheStreet, says Vertex Pharmaceuticals is the next big thing in biotech.